SemaglutideWeight Loss / GLP-1
GLP-1 receptor agonist studied for appetite and weight.
- Status
- Prescription
- Developer
- Novo Nordisk; brands Ozempic / Wegovy / Rybelsus
- Receptors / target
- GLP-1 receptor agonist (~94% homology to human GLP-1); glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, increased satiety
- FDA-approved?
- YES
- Prescription available?
- YES
- Studied for
- type 2 diabetesobesityweight losscardiovascular risk reduction
Overview
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist and an FDA-approved prescription medicine — not a research-only compound. It is marketed as Ozempic (subcutaneous, type 2 diabetes; 2017), Rybelsus (oral, type 2 diabetes; 2019) and Wegovy (subcutaneous, chronic weight management; 2021). Its elimination half-life of about one week supports once-weekly injection (or once-daily oral) dosing. This profile summarizes what the trials and FDA label report; it is not medical, dosing or treatment advice.
Mechanism
Per the FDA label, semaglutide is a GLP-1 analogue with roughly 94% sequence homology to human GLP-1 that binds and activates the GLP-1 receptor. It lowers blood glucose in a glucose-dependent way by stimulating insulin secretion and suppressing glucagon, and it slows gastric emptying and increases satiety, reducing food intake. Structural modifications resist enzymatic degradation and add albumin binding, which account for the long half-life.
Clinical evidence
Semaglutide has robust human RCT evidence. In the STEP 1 obesity trial (NEJM 2021), once-weekly subcutaneous semaglutide 2.4 mg produced a mean weight loss of ~14.9% versus 2.4% with placebo. In type 2 diabetes, SUSTAIN-6 (NEJM 2016) lowered the rate of cardiovascular death, nonfatal MI or nonfatal stroke versus placebo, and the large SELECT trial (NEJM 2023; 17,604 patients with established cardiovascular disease and overweight/obesity but no diabetes) showed a ~20% relative reduction in major adverse cardiovascular events.
Safety profile
The most common adverse reactions are gastrointestinal — nausea, vomiting, diarrhea, abdominal pain and constipation — usually mild-to-moderate and often transient. The label carries a boxed warning because semaglutide causes dose- and duration-dependent thyroid C-cell tumors in rodents; human relevance is undetermined, and it is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and in those with serious hypersensitivity. Other labeled risks include pancreatitis, gallbladder disease and (in diabetes) hypoglycemia with insulin or sulfonylureas. A prescription drug with serious labeled risks — these are observed findings, not guidance to use it.
- Weeks 1–4
Dose-escalation; nausea/GI effects are most common early as appetite is suppressed and initial weight loss begins.
- Weeks 8–28
Progressive weight loss and improved glycemic control through the SUSTAIN and STEP programs.
- ~Week 68
STEP 1 endpoint: ~14.9% mean weight loss; the effect plateaus near the trial end and is largely regained after stopping.
What people describe in forums, blogs and uncontrolled clinic write-ups — experiential and unverified, not clinical evidence and not medical advice.
- Large, sustained weight lossthe dominant reported outcome
The overwhelming reason people post is weight loss, and the transformations are often dramatic — r/Semaglutide is full of one- and two-year updates of 100+ lb losses, frequently by people who say they had plateaued for years despite dieting and exercise. Self-reported, but the volume and consistency mirror the clinical trial results.
Reddit — r/Semaglutide - 'Food noise' quiets downthe most cited subjective benefit
The single most repeated non-scale effect is the quieting of 'food noise' — the constant background chatter about food. Users describe finally being able to stop obsessing over meals and, in many cases, an end to binge-eating; one 100-lb-loss poster credits it directly with breaking that cycle. Widely echoed and unverified.
Reddit — r/Semaglutide - Confidence and comfort, not just the scalevery commonly reported
Beyond pounds, people describe feeling comfortable in their own skin, more confident and 'healthy and happy,' and say they try to focus on how they feel rather than the number. A genuinely common and positive theme, though it is subjective and intertwined with the weight loss itself.
Reddit — r/Semaglutide - Loose skin after major lossasked about on nearly every transformation post
On almost every big before/after, commenters immediately ask about loose skin — and posters often acknowledge it as the trade-off of fast, large weight loss, with some considering skin-removal surgery. A frequent, realistic caveat to the transformation stories rather than a benefit.
Reddit — r/Semaglutide - Regain and returning food noise after stoppinga recurring maintenance concern
Users who come off semaglutide commonly report that appetite and 'food noise' gradually return and some weight comes back — one two-year poster who stopped for six months notes food noise 'comes and goes' and a small regain. Reflects the well-known reality that it manages weight while taken rather than curing it. Anecdotal.
Reddit — r/Semaglutide
Reported in published literature and user reports. Not a complete list, and not medical advice.
- Nausea, vomiting, diarrhea, constipation
- Decreased appetite
- Injection-site reactions
- Gallbladder events; rare pancreatitis signal
If severe or unexpected symptoms occur, contact a qualified medical professional. PEPTIDES·INDEX does not provide medical advice.
- Personal or family history of medullary thyroid carcinoma (MTC), or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) — boxed warning; contraindicated per the FDA label.
- Known serious hypersensitivity to semaglutide or any product component.
- History of pancreatitis warrants caution; pregnancy is generally avoided given lack of safety data.
- Insulin or sulfonylureasIncreased risk of hypoglycemia; the label advises considering a dose reduction of the concomitant agent.
- Oral medicationsSlowed gastric emptying can affect absorption of co-administered oral drugs; relevant during dose escalation.
Compare
- vs Tirzepatide
Dual GIP/GLP-1 agonist with greater trial weight loss
- vs Cagrilintide
Amylin analog often paired with semaglutide as CagriSema
FAQ
Is semaglutide FDA-approved?
Yes. It is approved as Ozempic (injectable, type 2 diabetes), Rybelsus (oral, type 2 diabetes) and Wegovy (injectable, chronic weight management). It is a prescription medicine, not a research-only compound.
How much weight loss did the trials show?
In the STEP 1 obesity trial, once-weekly subcutaneous semaglutide 2.4 mg produced a mean weight loss of about 14.9% versus 2.4% with placebo over 68 weeks. The large SELECT trial also showed roughly a 20% relative reduction in major cardiovascular events in people with established cardiovascular disease.
Is it the same as tirzepatide?
No. Semaglutide acts only on the GLP-1 receptor, while tirzepatide is a dual GIP/GLP-1 agonist. In the SURPASS-2 head-to-head, tirzepatide produced greater HbA1c and weight reductions, though semaglutide has the larger cardiovascular outcome evidence base.
Is semaglutide injected or taken by mouth?
Both forms exist. Ozempic and Wegovy are once-weekly subcutaneous injections, while Rybelsus is a once-daily oral tablet. The injectable doses are titrated up to 2.4 mg over roughly 16 weeks. How any product is dosed is a decision for a prescriber.
What are the most common side effects?
Gastrointestinal effects — nausea, vomiting, diarrhea, abdominal pain and constipation — are most common and usually mild-to-moderate and transient. Labeled risks also include pancreatitis, gallbladder disease, and (in diabetes) hypoglycemia with insulin or sulfonylureas.
Is weight regained after stopping semaglutide?
Largely yes. The weight-loss effect depends on continued use; trial data show the effect plateaus near the end of the study period and much of the lost weight is regained after the drug is discontinued.
Related guides
GuideTirzepatide: The Complete Guide (2026)GuideRetatrutide Complete Guide: Phase 3 Results, Dosing, Side Effects & FDA StatusArticleRetatrutide vs Tirzepatide: Mechanism, Efficacy, Dosing & Cost (2026)ArticlePeptide Plugs Review (2026): COAs, Pricing & Is It Legit?ArticleBest Peptides for Weight Loss & Fat Loss in 2026: Cost & EvidenceSimilar compounds
Starting references for the library summary. These are not dosing instructions or medical advice.
For research-use educational context only. Not medical advice and not a recommendation to use any compound. Consult a qualified healthcare professional before any health decision.